Scarica l'app Stockscreener
29.01
7.76%
2.09
Dopo l'orario di chiusura:
29.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.92
Aprire:
$27.52
Volume 24 ore:
1.12M
Relative Volume:
0.87
Capitalizzazione di mercato:
$1.68B
Reddito:
$11.13M
Utile/perdita netta:
$-105.04M
Rapporto P/E:
-12.86
EPS:
-2.2565
Flusso di cassa netto:
$-81.54M
1 W Prestazione:
-4.35%
1M Prestazione:
-15.20%
6M Prestazione:
+409.84%
1 anno Prestazione:
+163.49%
Intervallo 1D:
$27.09
$29.12
Intervallo di 1 settimana:
$26.60
$30.93
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
29.01 | 1.62B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
CAPRICOR (CAPR) CFO exercises stock options to acquire 3,000 shares - Stock Titan
10,000-share sale amendment for CAPR (NASDAQ: CAPR) - Stock Titan
CAPR (NASDAQ: CAPR) lists recent purchases and awards in Form 144 - Stock Titan
(CAPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - MSN
Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN
Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $38 - Moomoo
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy - TipRanks
Capricor Therapeutics, Inc. Q1 2026 earnings preview - MSN
Capricor (CAPR) Q1 2026 Earnings Transcript - AOL.com
Capricor Therapeutics (CAPR) director boosts stake via 3,937-share option exercise - Stock Titan
CAPR: Capricor Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
CAPRICOR THERAPEUTICS, INC. 1Q 2026: Revenue $9.4M, EPS ($0.59) — 10-Q Summary - TradingView
[10-Q] CAPRICOR THERAPEUTICS, INC. Quarterly Earnings Report - Stock Titan
CAPR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
Capricor stock price target held at $63 by B.Riley on FDA progress - Investing.com UK
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript - Insider Monkey
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid Legal Challenges - GuruFocus
Capricor Therapeutics (CAPR) Provides Update on FDA Review and C - GuruFocus
Capricor Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Capricor Therapeutics Q1 Earnings Call Highlights - sharewise.com
Is Capricor Therapeutics (CAPR) Overvalued After Q1 2026 Update? - GuruFocus
Earnings call transcript: Capricor Therapeutics misses Q1 2026 EPS expectations - Investing.com India
Capricor Therapeutics: Runway Through 4Q27 >CAPR - Moomoo
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):